Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients

Table 1 Baseline Characteristics of 775 at-risk patients participating in hepatocellular carcinoma surveillance, 2018-2020

Characteristic		n = 775 (%)	mean ± SD	Median (IQR)
Age (years)			60.0 ± 12.2
Sex	Male	457 (59.0)
	Female	318 (41.0)
Ethnicity	Caucasian	442 (57.0)
	Asian	249 (32.1)
	African/Middle-Eastern	68 (8.8)
	Unreported	16 (2.1)
Primary language spoken	English	573 (73.9)
	Non-English	202 (26.1)
Indication for hepatocellular carcinoma surveillance	Cirrhosis	429 (55.3)
	Chronic HBV	343 (44.3)
	Chronic HCV with Advanced Fibrosis	3 (0.4)
Aetiology of Cirrhosis, n = 429	HBV hepatitis	58 (13.5)
	HCV hepatitis	136 (31.7)
	Alcoholic hepatitis	103 (24.0)
	NASH	64 (14.9)
	Non-viral, non-alcoholic, non-NASH cirrhosis1	68 (15.9)
HBV anti-viral use, n = 385	Yes	206 (53.5)
	No	179 (46.5)
Specialty care clinic	General hepatology2	453 (58.5)
	Pre-transplant	126 (16.3)
	Nurse-led surveillance	80 (10.3)
	Non-liver3	76 (9.8)
	Unspecified	40 (5.2)
MELD score, n = 429				9 (7-13)

¹Includes autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, cryptogenic cirrhosis.

²Includes general liver and outreach clinics.

³Includes clinics such as infectious diseases, renal, general medicine where patients received specialist care.

HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis; SD: Standard deviation.